For biotech startups
Accelerate your path from target to lead
Biotech startups move fast — but drug discovery doesn’t always follow. We help you identify high-quality hits and leads faster, with full IP ownership and no downstream obligations.
The startup reality
Built for the realities of early-stage biotech
Traditional screening platforms were built for big pharma. We were built for you.
Novel or hard-to-drug targets
Many early-stage programs pursue targets conventional methods can’t reach. Our in-cell platform expands your addressable target space.
Limited access to purified proteins
No purified target protein? No problem. Our cBTE technology screens directly in living cells — no protein prep required.
Investor and milestone pressure
Every day counts. Our platform delivers ranked hits with structural data in few months so you move forward with confidence, not uncertainty.
Small teams balancing science and strategy
You don’t need to build in-house screening capabilities. We slot in as your discovery partner and deliver results your team can act on.
“The earlier you find the right lead, the stronger your position, pipeline, and story.”
3rd gen
DEL technology — cBTE, BTE & YoctoReactor®
Lower
attrition rates through physiologically relevant screening
How it works
From target to lead — faster
A streamlined process designed to deliver high-quality hits with minimal input from your team and no need for expensive in-house infrastructure.
01
Target submission
Share your target — even if it’s novel, hard-to-express, or a membrane protein. No purified protein is required for our in-cell platform.
02
DEL screening
We screen hundreds of millions of compounds in a single experiment using our proprietary YoctoReactor® and BTE/cBTE technologies.
03
Ranked hits delivered
You receive ranked, actionable hits with structural data — ready for your team to validate and advance toward lead optimization.
Our platform
Technology that goes where others can’t
Three proprietary 2nd and 3rd generation DEL technologies, each designed for a different layer of biological complexity.
Library synthesis
YoctoReactor® (yR)
Creates vast small-molecule DELs with a perfect match between DNA barcodes and displayed compounds — the foundation for high-fidelity screening. Enables ultra-high screening capacity in a single experiment.
In vitro screening
Binder Trap Enrichment® (BTE)
A homogeneous in vitro screening technology for rapid, comprehensive DEL screening. Ideal for targets where purified protein is available and in vitro conditions are appropriate.
In-cell screening
Cellular BTE® (cBTE)
The world’s only technology for screening DELs inside a living cell. No purified protein needed. More physiologically relevant results from day one — expanding the target space to previously “undruggable” biology.
Startup-friendly model
You keep everything. Full stop.
Our collaboration model is designed to support your program through discovery and beyond — without adding complexity to your future commercialization path.
Full IP ownership
Your future programs and discoveries remain entirely yours — we have no reach into subsequent developments.
No downstream obligations
No milestone payments, royalties, or revenue share tied to future success. You own the outcome.
No reach-through rights
Your future programs and discoveries remain entirely yours — we have no reach into subsequent developments.
Full freedom to operate
Develop, license, partner, or sell your assets independently. Your program, your path, your terms.
Track record
Proven at scale. Accessible to startups.
Vipergen has worked with some of the world’s largest pharmaceutical companies — and brings that same platform to early-stage teams.
90+
Partnerships closed with pharma and biotech companies globally, including top-10 pharma in the US, EU, and Japan.
500M+
Drug-like molecules screened in a single experiment via the YoctoReactor® DEL synthesis platform — with high-fidelity barcode matching.
#1
The first and only company capable of screening DNA-encoded chemical libraries directly inside a living cell — a world first commercialized by Vipergen.
When to work with us
We’re the right partner when you need to move fast
Whether you’re at idea stage or preparing for your next funding milestone, Vipergen meets you where you are.
Validating a novel target
Generate real hit data against a new target without investing in protein production or assay development. Get answers before committing further.
Exploring new mechanisms of action
Screen across a broad chemical space to discover unexpected binding modes, allosteric sites, and novel chemotypes for your target class.
Preparing for a funding milestone
Hit data strengthens your pitch. Show investors a credible lead series with structural data — not just computational predictions or assay signals.
Hard-to-drug or membrane targets
GPCRs, ion channels, PPIs, and other challenging targets are precisely where in-cell DEL screening outperforms traditional in vitro methods.
Accelerating lead generation
Skip months of weak signal validation. Our ranked hit lists come with structural data so your chemists can prioritize and move to SAR immediately.
Expanding without expanding headcount
You don’t need to hire a screening team or build assay infrastructure. We are your discovery engine, and you stay focused on your core science.